Literature DB >> 14662941

Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus.

Jianduan Li1, Daniela S Gerhard, Zhengyan Zhang, Phyllis C Huettner, Jason Wright, Loan Nguyen, Danielle Lu, Janet S Rader.   

Abstract

Human papillomaviruses (HPVs) are important in the development of human cancers, including cervical and oral tumors. However, most existing methods for HPV typing cannot routinely distinguish among the more than 100 distinct types of HPV or the natural HPV intratypic variants that have also been documented. To address this problem, we developed a novel method, general primer-denaturing high-performance liquid chromatography (GP-dHPLC), for the detection and typing of genital HPV using an automated 96-well plate format. GP-dHPLC uses general primer PCR (GP-PCR) to amplify the viral DNA and then analyzes the GP-PCR products by denaturing high-performance liquid chromatography (dHPLC). A number of different primer pairs with homology to most known genital HPV types were tested, and the L1C1-L1C2M pair specific for the L1 region of the viral genome was chosen. A set of HPV standard control patterns, consisting of those for HPV types 16, 18, 31, 33, 39, 45, 51, 52, 56, 58, 59, 6, and 11, was established for genital HPV typing. One hundred eighty-six frozen and formalin-fixed cervical cancer tissue samples were analyzed for the presence of HPV and the HPV type by this method, and 95.8% of them were found to contain HPV DNA. GP-dHPLC accurately discriminated among HPV variants that differed by as little as one nucleotide. Several new variants of HPV types 16, 18, 39, 45, 52, and 59 were identified. Moreover, multiple HPV infections were detected in 26.6% of the samples. Our results indicate that HPV typing by GP-dHPLC permits discrimination of common genital HPV types, detection of multiple HPV infections, and identification of HPV variants in clinical samples.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14662941      PMCID: PMC309016          DOI: 10.1128/JCM.41.12.5563-5571.2003

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  39 in total

1.  Human papillomavirus type 16 E6 and E7 gene variations in Indian cervical cancer.

Authors:  M Radhakrishna Pillai; S Sreevidya; Brad H Pollock; P G Jayaprakash; Brian Herman
Journal:  Gynecol Oncol       Date:  2002-12       Impact factor: 5.482

2.  Analysis of E6 variants of human papillomavirus type 33, 52 and 58 in Japanese women with cervical intraepithelial neoplasia/cervical cancer in relation to their oncogenic potential.

Authors:  C Y Xin; K Matsumoto; H Yoshikawa; T Yasugi; T Onda; S Nakagawa; M Yamada; S Nozawa; S Sekiya; Y Hirai; K Shiromizu; T Fujii; Y Taketani
Journal:  Cancer Lett       Date:  2001-09-10       Impact factor: 8.679

3.  Increased risk of high-grade anal neoplasia associated with a human papillomavirus type 16 E6 sequence variant.

Authors:  Maria M Da Costa; Charissa J Hogeboom; Elizabeth A Holly; Joel M Palefsky
Journal:  J Infect Dis       Date:  2002-04-16       Impact factor: 5.226

4.  Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method.

Authors:  P E Gravitt; C L Peyton; R J Apple; C M Wheeler
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

5.  Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study.

Authors:  J Berumen; R M Ordoñez; E Lazcano; J Salmeron; S C Galvan; R A Estrada; E Yunes; A Garcia-Carranca; G Gonzalez-Lira; A Madrigal-de la Campa
Journal:  J Natl Cancer Inst       Date:  2001-09-05       Impact factor: 13.506

Review 6.  2001 Consensus Guidelines for the management of women with cervical cytological abnormalities.

Authors:  Thomas C Wright; J Thomas Cox; L Stewart Massad; Leo B Twiggs; Edward J Wilkinson
Journal:  JAMA       Date:  2002-04-24       Impact factor: 56.272

7.  Association of human papillomavirus type 58 variant with the risk of cervical cancer.

Authors:  Paul K S Chan; Ching-Wan Lam; Tak-Hong Cheung; William W H Li; Keith W K Lo; May Y M Chan; Jo L K Cheung; Augustine F Cheng
Journal:  J Natl Cancer Inst       Date:  2002-08-21       Impact factor: 13.506

8.  Human papillomavirus type 16 intratypic variant infection and risk for cervical neoplasia in southern China.

Authors:  Paul K S Chan; Ching Wan Lam; Tak Hong Cheung; William W H Li; Keith W K Lo; May Y M Chan; Jo L K Cheung; Li Ying Xu; Augustine F Cheng
Journal:  J Infect Dis       Date:  2002-08-05       Impact factor: 5.226

9.  Variation in the E2-binding domain of HPV 16 is associated with high-grade squamous intraepithelial lesions of the cervix.

Authors:  A Giannoudis; M Duin; P J Snijders; C S Herrington
Journal:  Br J Cancer       Date:  2001-04-20       Impact factor: 7.640

10.  Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease.

Authors:  C Kämmer; M Tommasino; S Syrjänen; H Delius; U Hebling; U Warthorst; H Pfister; I Zehbe
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

View more
  3 in total

1.  TP53, MDM2, NQO1, and susceptibility to cervical cancer.

Authors:  Xiaoxia Hu; Zhengyan Zhang; Duanduan Ma; Phyllis C Huettner; L Stewart Massad; Loan Nguyen; Ingrid Borecki; Janet S Rader
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-03       Impact factor: 4.254

2.  HLA-Cw group 1 ligands for KIR increase susceptibility to invasive cervical cancer.

Authors:  Maureen P Martin; Ingrid B Borecki; Zhengyan Zhang; Loan Nguyen; Duanduan Ma; Xiaojiang Gao; Ying Qi; Mary Carrington; Janet S Rader
Journal:  Immunogenetics       Date:  2010-09-21       Impact factor: 2.846

3.  CD83 polymorphisms and cervical cancer risk.

Authors:  Kelly J Yu; Janet S Rader; Ingrid Borecki; Zhengyan Zhang; Allan Hildesheim
Journal:  Gynecol Oncol       Date:  2009-05-15       Impact factor: 5.482

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.